Background & aims: Based on results from year 2 of a 5-year trial, in 2012 the US Food and Drug Administration approved the use of a magnetic device to augment lower esophageal sphincter function in patients with gastroesophageal reflux disease (GERD).
Merz North America has announced that Radiesse has received FDA approval for hand augmentation to correct volume loss in the...
Aim: A substantial proportion of major depressive disorder patients are treatmentāresistant to antidepressant therapy, who require augmentation drugs, or other treatments including electroconvulsive therapy or transcranial magnetic stimulation.
Aims: We conducted a systematic review and meta-analysis to search and quantify the evidence of psychological and pharmacological augmentation interventions for TRD.
Boston Scientific has received FDA approval for the EMBLEM MRI Subcutaneous Implantable Defibrillator (S-ICD) System, as well as magnetic resonance...
Urologists face a dilemma when a lesion identified on multiparametric magnetic resonance imaging is benign on image guided fusion biopsy.
The FDA allowed marketing of the Cerena Transcranial Magnetic Stimulator (TMS), from eNeura Therapeutics, the first device to relieve pain...
Treatment-resistant depression (TRD) is a subset of Major Depressive Disorder which does not respond to traditional and first-line therapeutic options. There are several definitions and staging models of TRD and a consensus for each has not yet been established.
Galderma announced that it has received FDA approval to market Restylane Lyft for cheek augmentation and the correction of age-related...
Objectives: To assess the efficacy and safety of ofatumumab versus teriflunomide in recently diagnosed, treatment-naive (RDTN) participants from ASCLEPIOS.